Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: A retrospective analysis

被引:51
|
作者
Katyal, S
Oliver, JH
Peterson, MS
Chang, PJ
Baron, RL
Carr, BI
机构
[1] Univ Pittsburgh, Med Ctr, Dept Radiol, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Med Ctr, Dept Transplantat Med, Pittsburgh, PA 15213 USA
关键词
D O I
10.2214/ajr.175.6.1751665
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. The purpose of this study was to use hepatic arterial phase helical CT to as sess tumor vascularity and predict the likelihood of response to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. MATERIALS AND METHODS. Helical CT findings for 57 patients with hepatocellular carcinoma were classified into one of three patterns of vascularity on the basis of the degree of tumor or liver enhancement during the hepatic arterial phase. Cases in which hypervascular lesions predominated were classified as a type 1 pattern. Cases in which hypovascular lesions predominated were classified as a type 2 pattern. Patients were classified as responders or nonresponders on the basis of the changes of tumor size revealed on CT after three transcatheter arterial chemoembolization treatments. RESULTS. We classified the 57 patients as 37 responders (65%) and 20 nonresponders (35%). A statistically significant correlation between the type 1 hypervascular pattern and response to transcatheter arterial chemoembolization was seen; conversely, the type 2 hypovascular pattern correlated with nonresponse to transcatheter arterial chemoembolization (chi-square = 7.85, p = 0.02). Patients classified as responders lived significantly longer than those classified as nonresponders with 12-, 24-, and 36-month survival rates of 90%, 67%, and 36%. respectively, for responders and 70%, 17%, and 10%, respectively, for nonresponders. CONCLUSION. We found that patients who responded to transcatheter arterial chemoembolization had prolonged survival (p < 0.01). Response correlated closely with tumor vascularity as shown on hepatic arterial phase helical CT.
引用
收藏
页码:1665 / 1672
页数:8
相关论文
共 50 条
  • [31] Prediction of Therapeutic Response of Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization Based on Pretherapeutic Dynamic CT and Textural Findings
    Park, Hyun Jeong
    Kim, Jung Hoon
    Choi, Seo-youn
    Lee, Eun Sun
    Park, Sang Joon
    Byun, Jae Young
    Choi, Byung Ihn
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2017, 209 (04) : W211 - W220
  • [32] TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION FOR HEPATOCELLULAR-CARCINOMA
    YANG, CF
    HO, YZ
    CHANG, JM
    CHIANG, RH
    LAI, KH
    LEE, SD
    TSAI, YT
    LUI, WY
    LIU, TJ
    CHEN, GH
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 23 : S26 - S28
  • [33] Transcatheter arterial chemoembolization in hepatocellular carcinoma - Reply
    Llovet, JM
    Castells, A
    Bruix, J
    HEPATOLOGY, 1998, 28 (05) : 1442 - 1443
  • [34] Hepatocellular carcinoma: treatment with transcatheter arterial chemoembolization
    Acunas, B
    Rozanes, I
    EUROPEAN JOURNAL OF RADIOLOGY, 1999, 32 (01) : 86 - 89
  • [35] TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION FOR HEPATOCELLULAR-CARCINOMA
    YANG, CF
    HO, YJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 31 : S86 - S88
  • [36] Unresectable hepatocellular carcinoma in cirrhosis - Survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization
    Farinati, F
    DeMaria, N
    Marafin, C
    Herszenyi, L
    DelPrato, S
    Rinaldi, M
    Perini, L
    Cardin, R
    Naccarato, R
    DIGESTIVE DISEASES AND SCIENCES, 1996, 41 (12) : 2332 - 2339
  • [37] Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study
    Xuhua Duan
    Hao Li
    Donglin Kuang
    Pengfei Chen
    Kai Zhang
    Yanliang Li
    Xiang He
    Cheng Xing
    Haibo Wang
    Yaoxian Liu
    Limin Xie
    Shixi Zhang
    Qiang Zhang
    Peixin Zhu
    Honglin Dong
    Jichen Xie
    Hui Li
    Yong Wang
    Ming Shi
    Guangbin Jiang
    Yandong Xu
    Shiqi Zhou
    Chunyu Shang
    Jianzhuang Ren
    Xinwei Han
    Hepatology International, 2023, 17 : 915 - 926
  • [38] Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study
    Duan, Xuhua
    Li, Hao
    Kuang, Donglin
    Chen, Pengfei
    Zhang, Kai
    Li, Yanliang
    He, Xiang
    Xing, Cheng
    Wang, Haibo
    Liu, Yaoxian
    Xie, Limin
    Zhang, Shixi
    Zhang, Qiang
    Zhu, Peixin
    Dong, Honglin
    Xie, Jichen
    Li, Hui
    Wang, Yong
    Shi, Ming
    Jiang, Guangbin
    Xu, Yandong
    Zhou, Shiqi
    Shang, Chunyu
    Ren, Jianzhuang
    Han, Xinwei
    HEPATOLOGY INTERNATIONAL, 2023, 17 (04) : 915 - 926
  • [39] Multimodality Treatment with Conventional Transcatheter Arterial Chemoembolization and Radiofrequency Ablation for Unresectable Hepatocellular Carcinoma
    Ashoori, N.
    Paprottka, P.
    Trumm, C.
    Bamberg, F.
    Kolligs, F. T.
    Rentsch, M.
    Reiser, M. F.
    Jakobs, T. F.
    DIGESTION, 2012, 85 (01) : 18 - 26
  • [40] Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization
    Seong, J
    Park, HC
    Han, KH
    Lee, DY
    Lee, JT
    Chon, CY
    Moon, YM
    Suh, CO
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (05): : 1331 - 1335